Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

65.31 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
9 Analysts Have This To Say About Incyte
Via Benzinga
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
From Incyte
Via Business Wire
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
NASDAQ:INCY is showing decent growth, but is still valued reasonably.
INCYTE CORP (NASDAQ:INCY) is not too expensive for the growth it is showing. 
Via Chartmill
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
From Incyte
Via Business Wire
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
Via Benzinga
NASDAQ:INCY stands out as a growth opportunity that won't break the bank.
NASDAQ:INCY is showing good growth, while it is not too expensive. 
Via Chartmill
Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday?
Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days. 
Via Benzinga
Topics Economy
Exposures Interest Rates
GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
NASDAQ:INCY, a growth stock which is not overvalued.
Despite its growth, NASDAQ:INCY remains within the realm of affordability. 
Via Chartmill
Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Via Benzinga
Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock
From Incyte Corporation
Via Business Wire
The 3 Best Biotech Stocks to Buy in May 2024
If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May. 
Via InvestorPlace
NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals.
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals. 
Via Chartmill
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024
INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation.
In the world of growth stocks, NASDAQ:INCY shines as a value proposition. 
Via Chartmill
Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends
Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow. 
Via Benzinga
Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists
From Incyte and Escient Pharmaceuticals
Via Business Wire
When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Incyte to Report First Quarter Financial Results
From Incyte
Via Business Wire
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates... 
Via Talk Markets
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia
From Incyte
Via Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Incyte
Via Business Wire
For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals.
INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals. 
Via Chartmill
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success. 
Via InvestorPlace
Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa
From Incyte Corporation
Via Business Wire
Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis
From Incyte
Via Business Wire
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.